Dr Reddy’s: Dr Reddy’s launches erectile dysfunction treatment drug in US – The Economic Times

Never miss a great news story!
Get instant notifications from Economic Times

Pharmaceuticals

LATEST NEWS

  • VVIP chopper case: Court orders in-camera proceedings for Rajeev Saxena
  • Rao appears in SC, apologies for transferring head of probe team in Muzaffarpur shelter home case
  • Robert Vadra appears before ED in Jaipur; Priyanka accompanies him
  • Poll code violated? BBMP App will spot it
  • Opposition parties working on common agenda

SENSEX

36,394-0.99

NIFTY 50

10,8912.05

GOLD (MCX) (Rs/10g.)

32,942-104.00

USD/INR

70.92-0.26

Portfolio

Loading…

Select Portfolio and Asset Combination for Display on Market Band

Select Portfolio

Select Asset Class

Show More

CREATE PORTFOLIO

ADD INVESTMENT

Download ET MARKETS APP

Get ET Markets in your own language

CHOOSE LANGUAGE

ENG

  • ENG – English
  • HIN – हिन्दी
  • GUJ – ગુજરાતી
  • MAR – मराठी
  • BEN – বাংলা
  • KAN – ಕನ್ನಡ
  • ORI – ଓଡିଆ
  • TEL – తెలుగు
  • TAM – தமிழ்
Drag according to your convenience

ET NOW RADIO

ET NOW

TIMES NOW

Tadalafil tablets are a therapeutic equivalent generic version of Adcirca tablets, Dr Reddy’s Laboratories said in a BSE filing.

Dr Reddy's launches erectile dysfunction treatment drug in US
„The Adcirca brand and generic had US sales of approximately USD 490 million for the most recent twelve months ending in November 2018.”
NEW DELHI: Dr Reddy’s Laboratories Tuesday said it has launched Tadalafil tablets, used to treat erectile dysfunction, in the US market.

Tadalafil tablets are a therapeutic equivalent generic version of Adcirca tablets, Dr Reddy’s Laboratories said in a BSE filing.

Quoting IMS Health data, Dr Reddy’s Laboratories said, the Adcirca brand and generic had US sales of approximately USD 490 million for the most recent twelve months ending in November 2018.

Shares of Dr Reddy’s were trading 0.01 per cent lower at Rs 2,616.70 apiece on the BSE.

Read more on

Dr Reddy’s

treatment drug

Pills

Tablets

US

erectile dysfunction

Also Read

Dr Reddy’s launches heartburn drug in US market

United Healthcare Services files complaint against Dr Reddy’s US arm

Dr Reddy’s gets FDA nod for ‚Tosymra’ migraine nasal spray

Buy Dr. Reddy’s Laboratories, target Rs 2675: Dr CK Narayan

Dr Reddy’s climbs 8% on nod for generic Suboxone

Commenting feature is disabled in your country/region.

Download The Economic Times Business News App for the Latest News in Business, Market & More.

  • 1

    Dr Reddy’s launches erectile dysfunction treatment drug in US

  • Traditional knowledge, cheaper drugs on India’s agenda for WTO

  • Glenmark Pharma gets USFDA nod for drug for patients on dialysis

  • Aurobindo acquires Apotex’s operations in 5 European countries

  • Two TB survivors fight Johnson & Johnson monopoly bid

  • United Healthcare Services files complaint against Dr Reddy’s US arm

  • Dr Reddy’s Laboratories Ltd appoints Axis Bank ex-MD Shikha Sharma as independent director

  • Culture of ‘bending rules’ in India challenges U.S. drug agency

  • Strides to exit investment in Arrow for AUD 394 million

  • Natco dares Novartis with new heart drug

  • Dr Reddy’s gets FDA nod for ‚Tosymra’ migraine nasal spray

Loading
Please wait…